Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve
<b>Background:</b> Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer’s disease, and aducanumab has been recalled. <b>Methods</b>: Recently, it was reported that the clinical tria...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/12/2918 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|